Topic

Molly Podolefsky, PhD, is the managing director of environmental, social, and governance at Stern Investor Relations.

Articles

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

Pharma's ESG Equation: Materiality and Strategy are Key

Veronica Sandoval, Phd, is the prinicpal of patient inclusion and health equity in the chief diversity office at Genetech.

Biopharma has a responsibility to meet patients where they are.

Harnessing the Power of Communities to Combat Healthcare Inequities

Meg Rivers is the former managing editor of 

Videos

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways companies can remain accountable for DE&I efforts in pharma in this Pharmaceutical Executive Podcast video.

DE&I Accountability in Pharma

Expansion aims to continue to create programs that address health and education inequities.

Novartis Reveals New Collaborators to Beacon of Hope Initiative 

Mike Hollan is an assistant managing editor for 

 and can be reached at mhollan@mjhlifesciences.com.

In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.

DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles

Smita Pillai is the global chief diversity, equity, and inclusion (DE&I) officer for Regeneron.

Building a culture of inclusivity is not an endpoint—but a journey. 

Why Life Sciences Companies Need Inclusive Leadership

Rose Blackburne, MD, MBA, vice president, global head, general medicine, PPD Clinical Research, Thermo Fisher Scientific, discusses health equity in pharma, specifically racial biases, and how the industry can address inequities in access and care going forward. 

Health Equity in Pharma: Communities Most Impacted by Racial Bias

What Smita Pillai, global chief diversity, equity, and inclusion (DE&I) officer, Regeneron, learned from two decades in DE&I roles.

Tough—But Rewarding: The Evolution of the Chief Diversity Officer

Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients. 

Janssen, Johns Hopkins Partner on Dermatology Ethnic Skin Program

Judith Kulich, principal, patient health and equity lead, ZS, and Nan Gu, associate principal, patient health and equity, ZS, discuss health equity in pharma, specifically racial biases, and how the industry can address access and inequities going forward. 